HONG KONG, Apr 9, 2025 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). SM17 uniquely binds to the co-receptor for IL-25, a key alarmin, and blocks downstream signaling – disrupting the inflammatory cascade driven by IL-25 engagement.SM17 Competitive Advantages:- First AD biologic with dual efficacy --- first and the only AD biologic that could reach both NRS-41 and EASI-752 responder rate over 60%3 simultaneously at end of treatment (EOT), comparing to marketed product.- Faster and deeper itch relief than anti-IL-4/13 agents4--- onset of anti-pruritus effect as early as Week 2 (SM17) vs Week 4~6 (other agents), over 90% of patients achieved NRS-4 (SM17) vs 30~40% of patients (other agents) at EOT.- Safer than JAK inhibitors5 --- No serious adverse events (SAEs) nor drug related Grade 3 or above adverse events (AEs) reportedï¼Œ minimum risk of serious infections or major adverse cardiovascular events (MACE).1 NRS-4: a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline2 EASI-75: ≥75% reduction from baseline in Eczema Area and Severity Index (EASI) score3 SM17 ph1b NRS-4 responder rate:91.7%, EASI-75 responder rate 75.0%4 Dupixent@ Prescribing information, SOLO-1 & SOLO-2 studies5 RINVOQ@ Prescribing information, Measure Up 1 & Measure Up 2 studiesThis Phase1b study, which evaluated two doses level of SM17 (200mg and 600mg, respectively), met its primary endpoints manifested as the safety profiles in patients with moderate-to-severe AD by demonstrating that SM17 was well-tolerated with no serious adverse event (SAE) or treatment-related adverse events (TRAEs) with grade 3 or above. In terms of efficacy, this study met all the secondary endpoints assessing pruritus, skin healing and AD patients’ quality of life by demonstrating remarkable differences between SM17 treatment groups and placebo group.This study was a 16-week, randomized, placebo-controlled, double-blind study to assess the tolerability, safety and efficacy of SM17 monotherapy in 32 adults with moderate-to-severe AD, most of whom were previously inadequate responder to topical corticosteroids (TCS). Patients with a history of biologic (Dupilumab) or systemic Janus kinase (JAK) inhibitor medication (Upadacitinib) were also enrolled in the study.At week 12, 75.0% of patientsï¼ˆ9 /12ï¼‰ in the higher dose group achieved ≥75% reduction from baseline in EASI-75, vs. 0.0% of patients in the placebo group, with difference of responder rate as 75.0%ï¼ˆ95% CIï¼š32.00~91.11ï¼‰. In the lower dose group, 50.0% of patients (6/12) achieved EASI-75, a 50.0% difference vs. placebo (95%CIï¼š9.27~74.62).In the higher dose group, 41.7% of patients (5/12) achieved a validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™) score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (vIGA-AD 0/1) at week 12, representing a 41.7% difference vs. placebo (95%CI: 2.28~68.05). In the lower dose group, 25.0% of patients (3/12) achieved this endpoint, a 25.0% difference vs. placebo (95%CI: -11.22~53.23).It is particularly noteworthy that 91.7% of patients (11/12) in the higher dose group achieved a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline (NRS-4) at week 12, vs. 0.0% of patients in the placebo group. Even in the lower dose group, 66.7% of patients (8/12) achieved this endpoint, remarkably different to that of the placebo group.With regard to the onset of action, SM17 showed obvious anti-pruritus effect as early as week 2 after the initial dose, in either the higher or the lower dose group. The altitude of improvement in pruritus for SM17 treatment groups increased alongside with dosing and reached a mean level of 68% and 57% reduction from baseline in PP-NRS score at week 12, for higher and lower dose groups, respectively, vs. 18% for placebo group. Improvement in pruritus was also maintained for both SM17 treatment groups until week 16, which was 6 weeks away from last dosing (week 10). Improvement in skin healing showed similar trends, with a mean level of 73% and 57% reduction from baseline in EASI score at week 12 for the 2 treatment groupsï¼Œvs. a mean level of 42% reduction from baseline in placebo group.In addition, this Phase 1b study also met the endpoint of EASI 50 and EASI 90 at week 12, as well as superior improvement comparing to placebo in other skin healing measures as SCORAD and AD body surface area (BSA), or patients’ life quality questionnaire - Dermatology Life Quality Index (DLQI).Major efficacy endpoints results were summarized in the table below.EndpointsSM17 Higher dose (N=12)SM17 Lower dose (N=12)Placebo (N=12)EASI 50(%)Week1283.366.725.0Week1691.758.325.0EASI 75 (%)Week1275.0500.0Week1641.741.70.0EASI 90 (%)Week1241.716.70.0Week1641.741.70.0IGA 0/1 (%)Week1241.725.00.0Week1633.341.70.0NRS-4 (%)Week1291.766.70.0Week1675.058.325.0Safety findings were generally consistent with the safety profile of SM17 previously observed in US Phase 1 and China Phase 1a bridging study. The most frequent TEAEs (≥10%) in SM17 groups were nasopharyngitis and urinary tract infectionï¼Œwith the overall incidence rate difference between the treatment group and the placebo group being less than 5%.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, said, "SM17 has the potential to become a first- and best-in-class therapy for atopic dermatitis (AD), a market where a single transformative therapy can achieve multibillion-dollar (US) annual revenue. Pruritus is the primary concern for most of the patients with moderate-to-severe ADï¼Œand scratching behavior triggered by itch is likely the key driving factor in recurrent chronic inflammatory cycle in AD. With a favorable safety profile and skin clearance comparable to the most effective existing therapies, SM17 also delivers exceptional efficacy in itch relief – the most critical unmet need for patients. By addressing these key gaps in current treatment options, SM17 is positioned to redefine the standard of care for this debilitating condition. We are accelerating our clinical programs and actively pursuing partnerships to maximize its global impact. Next, we anticipate initiating Phase 2 trials in adults with moderate-to-severe AD. Notably, preclinical studies have shown promising results for SM17 in treating other Type 2 allergic diseases such as asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF). These findings suggest that SM17 could become a versatile therapeutic for a range of Th2-driven diseases, extending its potential beyond AD as a first- and best-in-class option."About Atopic Dermatitis MarketAtopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis involving genetic predisposition, skin barrier dysfunction, immune system dysregulation, and environmental factors. The immunological characteristics of AD are dominated by the Th2 axis, involving mediators such as TSLP, IL-4, IL-13, IL-5, IL-33, IL-31, OX40, and the JAK/STAT signaling pathway. AD typically begins in infancy, with about 50% of patients developing symptoms before the age of one. The disease follows a chronic and relapsing course.Epidemiological studies indicate that there are at least 230 million AD patients worldwide, with China having a substantial patient population exceeding 70 million, of which moderate-to-severe cases account for approximately 28%. In comparison, the U.S. has an estimated 16.5 million adult AD patients, with moderate-to-severe cases making up around 40%.According to Precedence Research, the global AD drug market was value at 13.62 billion in 2023 and is projected to reach 13.62 billion in 2023 and is projected to reach 31.44 billion by 2034. Current treatment options vary in efficacy and include topical medications (e.g., corticosteroids [TCS], calcineurin inhibitors [TCI]), oral antihistamines, and biologics, each with its own advantages and limitations.While conventional therapies like TCS, TCI, and oral antihistamines remain standard treatments, biologics such as dupilumab have significantly improved patients' quality of life. However, limitations such as slow onset, insufficient itch relief, and long-term safety concerns leave many patients' needs unmet. Another drug, the JAK inhibitor upadacitinib, faces safety-related challenges. In 2024, dupilumab's global sales surpassed $14 billion, highlighting the immense potential of the AD market and driving pharmaceutical companies to accelerate the development of differentiated therapies. Currently, competition in the AD field is primarily focused on target innovation: Among the top 10 AD clinical targets in China and globally, seven overlap, with IL-4Rα and JAK1 being the top two. In terms of clinical phases, only 14% of China's AD trials are in Phase 3 or later, compared to 23% globally (excluding Phase 2/3 trials), indicating that China's strategy remains largely fast-follow. Moreover, China's target landscape is more concentrated, with the top three targets (IL-4Rα, JAK1, and PDE4) accounting for 46% of clinical trials, whereas global AD clinical targets are more evenly distributed.About SM17SM17 is a novel, First-in-Class (FIC), humanized, IgG4-κ monoclonal antibody, which is a global first in-class monoclonal antibody drug targeting IL-25 receptor with the potential for treating AD, asthma, idiopathic pulmonary fibrosis and other immunological disorders. SM17 could suppress Type 2 helper T (Th2) immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s) and Th2 cells, to block a cascade of responses induced by IL-25 and suppress the release of the downstream Th2 cytokines such as IL-4, IL-9 and IL-13. IL-25 is a critical cytokine classified as ‘‘alarmin’’, which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, especially in AD. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index (EASI) and patient’s quality of life, but they either are slow in response, especially in anti-pruritic effect, or have safety concerns. With the novel mechanism of action, SM17 hopefully will become a new and probably better treatment option for AD, which is fast in anti-pruritic response, effective in skin healing and safe, addressing the unmet medical needs not covered by current treatment modalities.About Differences in Targeting the Receptor (IL-25R) vs the Ligand (IL-25)Using AD as a model, stimulated skin will continuously release IL-25, and neutralizing IL-25 with antibodies does not instantly impart relief. SM17 uniquely blocks one of the IL-25 receptor subunits (IL-17RB) in a non-competitive manner. We have in-house data supporting that SM17 can block receptor signal transduction without affecting IL-25 engagement with the receptor, so SM17 can provide fast anti-pruritic and anti-inflammatory effects arising from IL-25/IL-25 receptor interactions.Additionally, the number of receptors on cell surface is limited, and if sufficient antibodies against the receptor are added and all receptors blocked, therapeutic response will persist regardless of the amount of IL-25 released. This is the case for SM17, which blocks the limited number of receptors on cell surface. Once fully occupied, it stops the signaling regardless of IL-25 levels. This allows a fast, long-lasting inhibition and avoids high-dose requirements.Contrarily, antibodies targeting IL-25 must neutralize the ligand directly, while AD skin continuously releases IL-25 such that anti-IL-25 therapies require high doses to “mop-up” all newly released IL-25. This delays itch and inflammation relief.About SinoMab BioScience LimitedSinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in mainland China. The Company's flagship product Suciraslimab (SM03) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. SM03 (Suciraslimab) has completed the Phase 3 clinical trial for RA in China and is pending NMPA’s marketing approval for RA in China. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren’s syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs.Media enquiriesStrategic Financial Relations LimitedVeron Ng Tel: +852 2864 4831Phoenix Fung Tel: +852 2114 4939Shannon Lei Tel: +852 2114 2881Will Cheng Tel: +852 2864 4894Email: sprg_sinomab@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

陽光保險聚焦主業發展 2024年總保費收入持續增至1,283.8億人民幣

04/10/2025

香港, 2025年4月9日 - (亞太商訊 via SeaPRwire.com) - 2024年，在保險業新「國十條」政策指引與大保險觀引領下，保險業努力做好金融「五篇大文章」，財產保險領域推動高質量發展付諸行動，人身保險領域持續深化重點領域改革，行業整體呈現增長態勢。陽光保險（6963.HK）聚焦主責主業，全面啟動並有序推進「新陽光戰略」，深化客戶行動，扎實價值發展，核心業務經營韌性持續凸顯。根據3月26日發佈的業績報告，於2024年，陽光保險實現總保費收入1,283.8億元（單位：人民幣，下同），同比增長8.0%；保險服務收入640.0億元，同比增長6.9%。歸屬於母公司股東的淨利潤54.5億元，同比增長45.8%。公司內含價值1,157.6億元，較上年末增長11.2%。2024年末，有效客戶數約3,019萬。在陽光保險集團業績發佈會上，董事長張維功對公司全年業績評價道：「如果用一句話來概括，就是看得准、抓得實、做得好！」壽險逐步深化多元佈局，價值發展動能顯著增強以價值發展理念為準繩，陽光人壽夯實多線並進發展優勢，發展質量不斷提升；強化資產負債聯動，實現業務結構、負債成本「雙優化」，經營發展「穩中有進」。2024年實現總保費收入804.5億元，同比增長7.8%；一年新業務價值51.5億元，同比增長43.3%。個險深入推進差異化經營管理，實施「強基工程」，「一身」隊伍穩健向好、結構優化；「兩翼」價值發展模式持續夯實，深耕客戶經營，打造績優隊伍，發展動能持續增強。2024年，個險實現總保費收入228.7億元，同比增長22.5%，其中新單期繳保費收入60.0億元，同比增長39.6%。同時，陽光人壽扎實推進「知心陽光」戰略，調研客戶近3萬人，以「三╱五╱七」產品體系為抓手，積極把握客戶需求變化，做細、做精客戶分類經營體系。2024年中高客戶經營穩步提升，有效保單累計首年標準保費15萬元及以上的客戶數增長22.7%，有效保單累計首年標準保費5萬元及以上的客戶數增長18.2%。順應科技發展趨勢，陽光人壽還持續推進「科技陽光」戰略落地，聚焦數字化轉型和智能技術應用，賦能銷售隊伍，優化客戶體驗，增強數字風控能力。例如2024年，陽光人壽上線「客戶家庭保險需求分析及保障規劃系統」，這一系統結合客戶家庭七大關鍵要素和具體情況，全面洞察保險需求及保障缺口，按照「三五七」邏輯構建智能化模型，一鍵生成個性化家庭保險規劃報告。財險加速重點領域創新佈局，業務結構持續優化通過加快金融「五篇大文章」重點領域的創新佈局，陽光財險業務保持較快增長，結構實現持續優化。2024年實現原保險保費收入478.2億元，同比增長8.1%。其中，非車險原保險保費收入同比增長16.7%，佔比44.2%，同比提升3.3個百分點。承保綜合成本率99.7%，實現承保利潤1.2億元。機動車輛險方面，陽光財險持續深化應用車險智能生命表，提升目標客群選擇、精準定價和科學配費能力，打造車險智慧理賠平台，推動渠道轉型升級，業務結構持續優化，車險核心管理能力進一步增強。2024年，車險原保險保費收入267.1億元，同比增長2.2%，承保綜合成本率99.1%，實現承保利潤2.4億元。其中，家用車保費佔比同比提升2.0個百分點，續保率同比提升0.2個百分點。非機動車輛險方面，陽光財險持續提升在國家重大基礎設施建設、鄉村振興、健康中國等領域的服務能力，不斷優化產品供給和服務保障，深化「夥伴行動」全量風險管理服務模式，增強非車經營管理能力。2024年，非車險原保險保費收入211.1億元，同比增長16.7%。其中，農險、政策性健康險等政策性業務同比增長94.8%。客戶經營方面，陽光財險持續深入洞察客戶需求，便捷客戶服務體系，豐富溫暖貼心、專業可信的服務產品。2024年個人車險客戶非車險產品購買比例達到57.8%，同比提升7.8個百分點，家用車續保率64.4%，同比持續提升。針對團體客戶，持續深化「夥伴行動」風險管理服務落地，尤其是在酒店、倉儲行業取得不錯成績。2024年，為超1.5萬個企業客戶提供科技減損和專業風險諮詢服務。其中，酒店客戶同比提升54.7%，服務客戶到期續保率達到97.0%。科技應用方面，堅持「數據智能+場景融合」，整合內外資源，深化全線上化和智能應用，著力培育保險科技領域競爭優勢，不斷提升客戶體驗和運營效率。如AI人傷圖片智能定損工具實現小額人傷案件傷情診斷及定損，使用率達到82.4%，累計處理小額人傷案件11萬餘件，有效降低定損偏離度、提升業務處理效率與公司的風險管控能力；搭建數智經營平台，實現關鍵指標智能化歸因分析，有效提升各級經營管理者的經營施策能力。此外，陽光保險緊跟政策號召，發揮使命擔當，履行社會責任，積極做好「五篇大文章」，2024年公司持續提升服務實體經濟質效，為實體經濟提供風險保障71萬億元，提供資金支持逾4,631億元。對於陽光保險來說，今年是陽光成立20周年的重要節點，作為本世紀成立的唯一上市的民營保險集團，陽光20年來取得的成就來自為何？張維功在業績發佈會上表示，「陽光靠的就是堅守初心的陽光文化、堅定不移的戰略定力以及守正出奇、創新變革。或許這正解釋了為何過往20年來，陽光保險成為了新世紀成立保險公司中的佼佼者。」2025年是中國「十四五」規劃的收官之年，也是落實保險業新「國十條」要求的第一個完整年度，對保險業意義重大。相信陽光保險將繼續在政策指引下，堅定深耕主業、堅持價值發展，不斷創新突破，扎實推進新陽光戰略，為下一個20年書寫全新篇章。 Copyright 2025 亞太商訊 via SeaPRwire.com.

ACN Newswire

智慧照明博覽及春燈展匯聚約15,000名環球買家

多項財務指標創歷史新高海天味業衝刺港股「中國調味品第一股」

04/08/2025

香港, 2025年4月8日 - (亞太商訊 via SeaPRwire.com) - 2025年中國政府報告提出要大力提振消費，全方位擴大國內消費需求，將為以調味品為代表的基礎消費品需求擴容提供長期支撐。剛需屬性顯著的中國調味品行業呈現「一超多強」局面，絕對龍頭海天味業（603288.SH）已於今年年初向港交所遞表，擬通過打造「A+H」雙上市平台，進一步推進其全球化戰略。於4月3日，海天味業發佈了2024年年度業績報告。報告顯示，過去一年，公司核心數據指標實現全面增長，營收、淨利潤、品類銷值等多項指標均創歷史新高。其中，營業收入達人民幣269.01億元，同比增長9.53%；歸屬于上市公司股東的淨利潤約人民幣63.44億元，同比增長12.75%；基本每股收益人民幣1.14元，同比增加12.87%。推動「綠色智能釀造」升級，厚植新質生產力在中國調味品行業，海天味業是獨佔鰲頭的領軍企業，也是A股消費板塊最具知名度的龍頭之一。其最早源於明朝萬歷年間，迄今已擁有400餘年的歷史傳承，基於傳統工藝釀造的「最正宗中國醬油味道」，廣受中國消費者的廣泛認可和喜愛，形成了海天醬油在中國市場當仁不讓的領先地位，並鑄就了家喻戶曉的國民品牌。作為中國首批「中華老字號」企業之一的海天味業，在傳承傳統技藝的同時，也在積極創新求變，通過AI、物聯網、大數據等技術的全鏈條應用，促進傳統釀造工藝與前沿數智技術深度融合，推動傳統釀造業從「經驗驅動」向「數據驅動」跨越式升級，開闢出一條「綠色智能釀造」的可行路徑。通過多個維度的現代化和數字化轉型，海天味業構建了全球範圍內的技術壁壘，塑造在國際市場的雄厚競爭實力，持續引領和開創全球醬油智能釀造新時代。在原材料選擇方面，自主研發「AI 豆臉技術」，從源頭保障醬油風味的穩定性。在生產過程，採用 316L 食品級不銹鋼管道與全封閉車間，並創新研發AI智能檢測與信息加密技術。在產品品鑒方面，首創「AI 電子鼻」，大幅提升識別準確率。以新思維、新思路推進新型工業化，構建綠色智慧體系，海天味業打造出可持續的智能製造生態，智能釀造達世界最頂級水平，新質生產力加速培育。2025年1月14日，公司旗下高明工廠借超5項世界頂級智能釀造技術，晉升為全球唯一醬油釀造「燈塔工廠」，奠定了中國醬油智能釀造的「全球第一」地位。依託頂尖的智能釀造技術，海天味業響應「健康中國」戰略要求，緊跟消費市場趨勢，不斷將科研成果轉化為高品質產品，構建了健康化、個性化的健康產品矩陣。2024年，公司有機系列產品表現尤為突出，其中通過中美歐三方有機認證的有機醬油、有機黃豆醬，和有機穀物釀造的有機香醋等，已成為健康消費浪潮下的明星單品。針對現代消費者對低糖、低脂、低鹽需求，公司推出的高鮮味極鮮醬油、橘子醋、白灼汁等系列產品，亦迅速搶佔細分市場。此外，海天味業密切關注企業與環境的協同發展，圍繞應對氣候變化、水資源管理、循環經濟與包裝材料、綠色運營管理四個方面推進綠色實踐，致力將運營對環境的影響降至最低，實現企業的可持續發展， ESG治理成果卓著。旗下高明工廠更是將固廢填埋轉移率控制在99.89%以上，並因此獲SGS鑽石級「零填埋認證」，這也是固廢處理領域的最高認可。南寧工廠和高明工廠還相繼榮獲當地「無廢工廠」稱號。高明工廠亦實現96%的冷卻水回收率，並再次獲得廣東省「節水標杆公司」稱號。業績持續穩健增長，打造民族品牌出海標杆自2014年A股上市至今，海天味業一直保持穩健持續的增長，營收從人民幣98億元增長超170%至269億元。於2013年至2023年，公司是全球調味品前十大企業中，唯一實現收入雙位數複合增長的企業。2024年，憑藉著持續的研發投入、產品「推新」、渠道完善、服務升級等綜合性措施，公司繼續實現逆勢增長，歸屬於上市公司股東的淨資產人民幣 308.95 億元，同比增長 8.29%；整體淨利率23.63%，同比增加0.65%。行業領先的商業模式下，海天味業堅定長期發展定位，在消費需求洞察、創新研發攻堅和品牌塑造等領域持續深耕，塑造了強勁的發展韌性。公司不但擁有深入億萬消費者味蕾記憶的國民產品和產品家族，顯著的質量、效率、成本優勢，也具有行業最廣泛和最下沉的立體化全國銷售網絡，使其增長及盈利兼備，2024年業績強勢向好，成為投資者一致看好的「質優股」。與此同時，公司還大手筆分紅，擬按每10股派發2024年度現金股利人民幣8.60元(含稅)，股利支付率75.24%，現金分紅金額達人民幣47.73億元（含稅），為歷年最高。A股上市以來，海天味業累計派現人民幣311.91億元，近三年累計現金分紅（派現+回購）人民幣122.41億元，積極回饋股東，與投資者共享公司發展成果。而隨著近年來中餐文化在全球的廣泛普及，越來越多的中餐連鎖海外開店，以醬油為首的中餐調味品借中餐飲食的流行推廣逐漸走上西方餐桌，並日益受到全球消費者青睞。據統計，目前全球華人數量已超6,000萬，海外中餐飲食人群基數龐大，但中國調味品的海外供應遠未達到市場需求，增長空間巨大。海天味業逆勢增長的實踐，也為更多中國企業贏得全球性的長期競爭力提供了可借鑒的範本。正是看到了調味品海的廣闊機遇及行業全球化出浪潮的興起，海天味業計劃登陸港股市場，並以之為起點，依託深厚的中國釀造底蘊和領先世界的智能釀造水平，加快品牌出海，不斷推動中國智造的調味品走向全球，進一步提升國際品牌形象及競爭力，持續釋放國際市場增長潛力，致力於成為「全球第一醬油品牌」。 Copyright 2025 亞太商訊 via SeaPRwire.com.

ACN Newswire

FOURTH PARADIGM ANNOUNCES 2024 ANNUAL RESULTS

04/08/2025

Financial Highlights:- In 2024, the total revenue amounted to RMB5,261 million, representing a YoY increase of 25.1% - The revenue of the 4Paradigm Sage AI Platform (the “Sage AI Platform”) business grew by 46.7% YoY to RMB3,676 million, accounting for 69.9% of the total revenue - The SHIFT Intelligent Solutions business recorded revenue of RMB1,022 million, accounting for 19.4% of the total revenue - The revenue of the 4Paradigm SageGPT AIGS Services segment amounted to RMB563 million, accounting for 10.7% of the total revenue- Gross profit was RMB2,245 million, with a gross profit margin of 42.7%- The total R&D expenses reached RMB2,170 million, accounting for 41.2% of revenue- The annual loss attributable to the owners of the Company was RMB269 million, with a reduction of RMB640 million compared to the full year of 2023, narrowing by 70.4% YoY. This marks the fourth consecutive fiscal year of sequential loss reduction since 2021Operation Highlights:- In 2024, the number of lighthouse users served by the Company reached 161, a YoY increase of 16%. The average revenue per lighthouse user was RMB19 million, with a Net Dollar Expansion Rate (NDER) of 110% for lighthouse users in 2024- 4ParadigmSage: During the Reporting Period, the Company launched the vertical world model development and management platform, Sage AI Platform 5.0, and completed multiple minor version upgrades, achieving end-to-end capabilities across the computing layer, platform layer, model layer, and application layer- 4Paradigm SHIFT: During the Reporting Period, the Company launched multiple solutions targeting various application scenarios and continued to update and iterate the functionalities and effectiveness of existing solutions to meet enterprise requirements for accuracy, reliability, and real-time performance in different vertical scenarios- 4Paradigm AIGS: During the Reporting Period, the Company continued to upgrade and optimize the functionality and application performance of products, such as the enterprise software reconfiguration assistant AIGS Builder and the enterprise programming assistant AIGS CodeX, creating an enterprise-level “development assistant” that understands customers, businesses, knowledge and R&D, while enabling fast coding capabilitiesHONG KONG, Apr 1, 2025 - (ACN Newswire via SeaPRwire.com) - A leading enterprise AI software company - Beijing Fourth Paradigm Technology Co., Ltd. (“Fourth Paradigm” or the “Company”, Stock Code: 6682.HK) today announced the consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).In 2024, Fourth Paradigm achieved strong growth in its overall business. The Company’s total revenue reached RMB5,261 million, representing a YoY increase of 25.1%. Gross profit was RMB2,245 million, with a gross profit margin of 42.7%. The Company highly values technological R&D, and has clear profitability goals. During the Reporting Period, the R&D expenses reached RMB2,170 million, accounting for 41.2% of revenue. The annual loss attributable to the owners of the Company was RMB269 million, with a reduction of RMB640 million compared to the full year of 2023, narrowing by 70.4% YoY. This marks the fourth consecutive fiscal year of sequential loss reduction since 2021.In 2024, Fourth Paradigm committed to creating value for customers, continuously enhancing digital transformation experience for existing customers and increasing user stickiness. During the Reporting Period, the number of lighthouse users served by the Company reached 161, a YoY increase of 16%. The average revenue per lighthouse user was RMB19 million, with a Net Dollar Expansion Rate (NDER) of 110% for lighthouse users in 2024.Benefiting from the surge in AI market demand, the Company’s Sage AI Platform business achieved significant growth, driving steady performance improvement of core business. In March 2024, Fourth Paradigm launched Sage AI Platform 5.0, which integrates vertical world model development and management, enterprise AI agent application suites, GPU resource pooling and other end-to-end capabilities, supporting the large-scale production and application of vertical world models and enterprise AI agents, and continuously driving intelligent transformation and high-quality development across industries.Core business revenue increased by 46.7%, with scaled expansion driving rapid businessAs the core of the Fourth Paradigm’s all businesses, the 4Paradigm Sage AI Platform business achieved significant growth during the Reporting Period, with revenue reaching RMB3,676 million, representing a YoY increase of 46.7% and accounting for 69.9% of total revenue. Scale effects are deepening progressively.In 2024, Fourth Paradigm remained committed to technological innovation, comprehensively enhancing the capabilities of Sage AI Platform. On the basis of end-to-end capabilities across the computing layer, platform layer, model layer, and application layer, Sage AI Platform continued to optimize key capabilities such as AI agent and GPU resource pooling. Among these, AI agent further enhanced its ability to solve complex problems and improve execution accuracy, and developed the enterprise AI agent development platform that covers the entire lifecycle of AI agent design, development, debugging, deployment, operational analysis, and iterative optimization. This empowers enterprise developers to efficiently and scalably build business AI agents with cognitive, decision-making, and execution capabilities – all on demand. As a result, development cycles have been reduced by over 95% in most cases. The GPU resource pooling capability enables enterprises to achieve platform-level management of hardware clusters, on-demand allocation of computing resources, and rapid scheduling, helping to address challenges such as low utilization of heterogeneous computing resources and high costs of adapting large models to computing power. According to the latest report from the internationally authoritative research firm IDC, Fourth Paradigm has maintained its position as the leader in China’s machine learning platform market share for six consecutive years.While scaling its core business, Fourth Paradigm has also made steady progress in its two other major businesses – SHIFT Intelligent Solutions business and 4Paradigm AIGS service business, which provide strong support for the core business – Sage AI Platform, driving efficient growth across the overall business.During the Reporting Period, revenue from SHIFT Intelligent Solutions totaled RMB1,022 million, comprising 19.4% of the total revenue. This business is built on the Sage AI Platform, tailored to different industry business scenarios. These solutions enable Fourth Paradigm’s technology and capabilities to penetrate a wider range of industries and scenarios, addressing critical business challenges for traditional enterprises and driving digital and intelligent transformation across industries. Due to the impact of the business expansion strategy, the revenue from this business decreased by 20.3% YoY while the revenue from Sage AI Platform business achieved 46.7% YoY growth.In addition, the revenue from the 4Paradigm SageGPT AIGS Services business during the Reporting Period reached RMB563 million, accounting for 10.7% of the Company’s total revenue. This business provides efficient development tools and services based on generative AI for the Sage AI Platform business, enabling multi-fold increases in enterprise R&D productivity.“AI agent + Vertical World Model” dual-core architecture builds the AGI foundation, enabling continuous expansion of the business ecosystemIn recent years, the continuous advancement of generative AI technologies has accelerated progress toward Artificial General Intelligence (AGI), a consensus widely recognized across the industry. As an enterprise with over a decade of experience in the AI sector, Fourth Paradigm is committed to empowering industries through its core philosophy of “AI agent + Vertical World Model”, which uses AI agents to understand human needs and leveraging corresponding vertical world models to solve problems, while continuously enhancing their respective capabilities – will ultimately drive the realization of AGI.Over the past year, adhering to the philosophy of “AI agent + Vertical World Model”, Fourth Paradigm has collaborated with numerous industry partners and has successfully implemented hundreds of reliable and controllable enterprise-level AI agent applications, covering scenarios such as financial credit risk control, water and electricity equipment maintenance, hydrological data monitoring, chronic disease management, intelligent course learning, automotive manufacturing MES system management, fluid dynamics design, intelligent after-sales customer service and academic administration assistant, comprehensively driving the intelligent transformation for enterprises.At the same time, Fourth Paradigm, in collaboration with partners, has released several out-of-the-box user-level agent solutions, such as intelligent meeting solutions, intelligent mouse solutions, and desktop AI search tools. These solutions cover AI agent capabilities such as simultaneous interpretation, one-click translation, robotic assistants, AI writing, and intelligent cross-platform search, helping enterprise business personnel achieve a leap in daily work efficiency.In addition, since the advent of DeepSeek, the inference and deployment costs of large models have significantly decreased, catalyzing market demand across large model implementation, integrated solutions deployment, and on-device AI applications. Fourth Paradigm has rapidly iterated its technical capabilities and product adaptations to deliver high-value solutions addressing these market needs.In terms of integrated solutions, Fourth Paradigm launched the out-of-the-box SageOne IA large model inference integrated solution, which enables seamless switching between the full-capacity model and multiple distilled models while supporting mainstream large models. This increases GPU utilization by over 30% and improves inference performance by an average of 5-10 times. Furthermore, SageOne IA comes with a rich suite of AI applications, helping developers efficiently create enterprise-level generative AI applications.For on-device AI, Fourth Paradigm launched the ModelHub AIoT on-device inference solution. This solution allows users to easily deploy small-sized distilled models such as DeepSeek R1, Qwen 2.5, and Llama 2/3 series on on-device devices for offline operation. It also balances model compression and inference performance while addressing the complexities of deployment and optimization. In addition, the Company has further expanded these capabilities into the consumer electronics sector, delivering AI Agent solutions that integrate hardware and software. That empowers consumer electronics manufacturers to launch AI-enabled terminal products that resonate with their users.In terms of Strategic Outlooks, Dr. Dai Wenyuan, Chairman of the Board, Executive Director, Chief Executive Officer and General Manager of Beijing Fourth Paradigm Technology Co., Ltd. said, “In recent years, generative AI has gained widespread recognition globally. As an AI technology service provider with over a decade of experience in the enterprise service sector, we have a deeper and more accurate understanding of how to organically integrate these rapidly evolving AI technologies to empower our enterprise clients, create tangible business value, and deliver practical efficiency improvements for both enterprises and individuals. This aligns with our ultimate vision that has always guided our business – AI for Everyone. Looking ahead, we will build on our decade-long expertise in the enterprise service sector, look toward the broader AI market, and leverage our AI capabilities to transform all possible business domains. We believe that the convergence of these diverse capabilities will form the cornerstone for achieving AGI.” Copyright 2025 ACN Newswire via SeaPRwire.com.

ACN Newswire

JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong

04/08/2025

HONG KONG, Apr 3, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited (“JBM Healthcare”; Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, announced today that it has acquired a 90% stake in Tin Hee Tong Medicine Factory, Limited (“Tin Hee Tong”,), at a total consideration of HK$171.0 million. Tin Hee Tong has now become a non-wholly owned subsidiary of JBM Healthcare.Strengthening the Portfolio with a Trusted Heritage BrandTin Hee Tong’s flagship product, Tin Hee Tong Tin Hee Pills, has a rich legacy and strong brand recognition across Hong Kong and Mainland China, particularly in Guangdong Province. The product is well formulated for regulating the female menstrual cycle, promoting reproductive health, and enhancing blood circulation for a radiant complexion. Tin Hee Tong Tin Hee Pills is a highly trusted brand for gynecological well-being among female consumers. Recognising its distinctive market position and long-term growth potential, the Group sees this acquisition as a valuable strategic fit for its proprietary Chinese medicines portfolio.Unlocking Growth Potential & SynergiesThe acquisition presents a compelling opportunity to expand the Group’s portfolio of proprietary Chinese medicines and accelerate its growth strategy. By integrating this iconic brand into its existing lineup, the Group is well-positioned to capitalise on rising consumer demand for holistic healthcare solutions.To maximise the brand’s potential, the Group plans to launch a comprehensive marketing campaign, leveraging its extensive expertise in brand management and revitalisation to boost consumer awareness and engagement. Additionally, the Group will expand distribution networks to capitalise on new market opportunities and customer segments. By combining the complementary strengths of both businesses, the acquisition is expected to generate significant synergies, reinforcing the Group’s strategy of acquiring assets that align with its long-term vision and create shareholders’ value.Proven Track Record in Brand RevitalisationThe Group has a proven track record of revitalising heritage proprietary medicines brands, effectively transforming legacy products into prominent market players. Its portfolio includes iconic brands such as Po Chai Pills — a market leader in proprietary Chinese gastrointestinal medicines, Ho Chai Kung — a widely recognised household name in the OTC pain killer category, and Flying Eagle Woodlok Oil — a rejuvenated brand in the traditional Chinese medicated oil sector, driven by creative advertising that blends Hong Kong nostalgia with broad consumer appeal.Through strategic brand revitalisation, omni-channel expansion, and digitally driven consumer engagement strategies, the Group has successfully transformed heritage brands into contemporary wellness solutions that resonate with both loyal customers and the younger, generations. With Tin Hee Tong Tin Hee Pills, JBM Healthcare is set to reinvigorate this trusted brand and expand its market presence.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare said, “The acquisition of Tin Hee Tong represents a pivotal step in strengthening our leadership in the proprietary Chinese medicines sector. With its rich heritage and strong recognition, Tin Hee Tong Tin Hee Pills is a highly complementary addition to our portfolio. Drawing on our proven brand revitalisation expertise, we are confident in unlocking its full growth potential and delivering long-term value to our shareholders.”About JBM (Healthcare) Limited; Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills , Ho Chai Kung Tji Thung San , Tin Hee Tong Tin Hee Pills , Flying Eagle Woodlok Oil , Tong Tai Chung Woodlok Oil , Shiling Oil , Konsodona Medicated Oil , Contractubex and Mederma for Kids . JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

1 …105 106 107 108 109 … 177